186 related articles for article (PubMed ID: 15177501)
1. Tumour burden and interleukin-2 dose affect the interaction between low-dose total body irradiation and interleukin 2.
Safwat A; Aggerholm N; Roitt I; Overgaard J; Hokland M
Eur J Cancer; 2004 Jun; 40(9):1412-7. PubMed ID: 15177501
[TBL] [Abstract][Full Text] [Related]
2. Low-dose total body irradiation augments the therapeutic effect of interleukin-2 in a mouse model for metastatic malignant melanoma.
Safwat A; Aggerholm N; Roitt I; Overgaard J; Hokland M
J Exp Ther Oncol; 2003; 3(4):161-8. PubMed ID: 14567287
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma.
Safwat A; Schmidt H; Bastholt L; Fode K; Larsen S; Aggerholm N; von der Maase H
Radiother Oncol; 2005 Nov; 77(2):143-7. PubMed ID: 16216360
[TBL] [Abstract][Full Text] [Related]
4. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide.
Cao X; Zhang W; Wan T; Yu Y; Tao Q; Wang J
J Exp Clin Cancer Res; 1999 Jun; 18(2):173-9. PubMed ID: 10464704
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
Winkelhake JL; Stampfl S; Zimmerman RJ
Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
[TBL] [Abstract][Full Text] [Related]
7. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
Lafreniere R; Rosenberg SA
Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
[TBL] [Abstract][Full Text] [Related]
8. Alterations of tumour cells, stroma and apoptosis in rat prostatic adenocarcinoma following treatment with histamine, interleukin-2 and irradiation.
Johansson S; Landström M; Henriksson R
Anticancer Res; 1999; 19(3A):1961-9. PubMed ID: 10470141
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-gamma.
Lumsden AJ; Codde JP; Van der Meide PH; Gray BN
Anticancer Res; 1996; 16(3A):1145-54. PubMed ID: 8702226
[TBL] [Abstract][Full Text] [Related]
10. The mechanism of local tumor irradiation combined with interleukin 2 therapy in murine renal carcinoma: histological evaluation of pulmonary metastases.
Dezso B; Haas GP; Hamzavi F; Kim S; Montecillo EJ; Benson PD; Pontes JE; Maughan RL; Hillman GG
Clin Cancer Res; 1996 Sep; 2(9):1543-52. PubMed ID: 9816331
[TBL] [Abstract][Full Text] [Related]
11. Combined interleukin 1 beta/interleukin 2 treatment in mice: synergistic myelostimulatory activity and protection against cyclophosphamide-induced myelosuppression.
Proietti E; Tritarelli E; Gabriele L; Testa U; Greco G; Pelosi E; Gabbianelli M; Belardelli F; Peschle C
Cancer Res; 1993 Feb; 53(3):569-76. PubMed ID: 8425189
[TBL] [Abstract][Full Text] [Related]
12. Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma.
Soiffer RJ; Chapman PB; Murray C; Williams L; Unger P; Collins H; Houghton AN; Ritz J
Clin Cancer Res; 1997 Jan; 3(1):17-24. PubMed ID: 9815532
[TBL] [Abstract][Full Text] [Related]
13. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors.
Sampath P; Hanes J; DiMeco F; Tyler BM; Brat D; Pardoll DM; Brem H
Cancer Res; 1999 May; 59(9):2107-14. PubMed ID: 10232596
[TBL] [Abstract][Full Text] [Related]
14. Radiation therapy enhances the therapeutic effect of immunotherapy on pulmonary metastases in a murine renal adenocarcinoma model.
Chakrabarty A; Hillman GG; Maughan RL; Ali E; Pontes JE; Haas GP
In Vivo; 1994; 8(1):25-31. PubMed ID: 8054507
[TBL] [Abstract][Full Text] [Related]
15. Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors.
Papa MZ; Yang JC; Vetto JT; Shiloni E; Eisenthal A; Rosenberg SA
Cancer Res; 1988 Jan; 48(1):122-9. PubMed ID: 3257159
[TBL] [Abstract][Full Text] [Related]
16. The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma.
Donohue JH; Rosenstein M; Chang AE; Lotze MT; Robb RJ; Rosenberg SA
J Immunol; 1984 Apr; 132(4):2123-8. PubMed ID: 6607956
[TBL] [Abstract][Full Text] [Related]
17. The role of interleukin-2 in cancer therapy.
Kohler PC; Sondel PM
Cancer Surv; 1989; 8(4):861-73. PubMed ID: 2701732
[TBL] [Abstract][Full Text] [Related]
18. Decrease in interleukin 2-induced vascular leakage in the lungs of mice by administration of recombinant interleukin 1 alpha in vivo.
Puri RK; Travis WD; Rosenberg SA
Cancer Res; 1989 Feb; 49(4):969-76. PubMed ID: 2783561
[TBL] [Abstract][Full Text] [Related]
19. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG
Clin Cancer Res; 1997 Sep; 3(9):1661-7. PubMed ID: 9815857
[TBL] [Abstract][Full Text] [Related]
20. Cytosine deaminase-uracil phosphoribosyltransferase and interleukin (IL)-12 and IL-18: a multimodal anticancer interface marked by specific modulation in serum cytokines.
Khatri A; Husaini Y; Ow K; Chapman J; Russell PJ
Clin Cancer Res; 2009 Apr; 15(7):2323-34. PubMed ID: 19318483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
